BioSpace News Archive

Cardio Diagnostics Holdings, Inc. announced that the American Medical Association has granted and assigned a dedicated Current Procedural Terminology Proprietary Laboratory Analysis code, 0439U, for the company’s AI-driven coronary heart disease event risk assessment test, Epi+Gen CHD.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024 at 10:30 a.m. PT.

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024, at 1:30 PM PST.

AbelZeta Pharma, Inc. today announced the formation of a Scientific Advisory Board (the “SAB”) to advance its cell therapies for the treatment of inflammatory and immunological diseases.

Orca Bio today announced that Ivan Dimov, Ph.D., Orca Bio’s co-founder and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference.

The National Advisory Committee on Immunization’s (NACI) annual Statement on Seasonal Influenza Vaccine for 2024-2025 continues to recommend Fluzone® High-Dose Quadrivalent (Influenza Vaccine) among the preferential influenza vaccines to protect adults 65 years of age and older against influenza.

IceCure Medical Ltd. (Nasdaq: ICCM), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the publication of a study titled “Piezo1 facilitates optimal T cell activation during tumor challenge” in the highly influential peer-reviewed journal OncoImmunology.

Alcyone Therapeutics Inc. announced the first patient implanted in the PIERRE pivotal study to evaluate the safety and performance of the ThecaFlex DRx System.

Entera Bio Ltd. announced that, on December 27, 2023, it received an extension of 180 calendar days from the Nasdaq Stock Market LLC (“Nasdaq”) to regain compliance with the Nasdaq’s minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

Pfizer Canada ULC announced that Health Canada approved BEQVEZ (fidanacogene elaparvovec), an adeno-associated viral (AAV) vector-based gene therapy for the treatment of adults (aged 18 years or older) with moderately severe to severe hemophilia B.